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Background: The offer of prenatal Down’s syndrome screening is part of routine antenatal care in most of Europe;
however screening uptake varies significantly across countries. Although a decision to accept or reject screening is
a personal choice, it is unlikely that the widely differing uptake rates across countries can be explained by variation
in individual values alone.
The aim of this study was to compare Down’s syndrome screening policies and programmes in the Netherlands,
where uptake is relatively low (<30%) with England and Denmark where uptake is higher (74 and > 90%
respectively), in an attempt to explain the observed variation in national uptake rates.
Methods: We used a mixed methods approach with an embedded design: a) documentary analysis and b)
expert stakeholder analysis. National central statistical offices and legal documents were studied first to gain
insight in demographic characteristics, cultural background, organization and structure of healthcare followed by
documentary analysis of primary and secondary sources on relevant documents on DSS policies and programme.
To enhance interpretation of these findings we performed in-depth interviews with relevant expert stakeholders.
Results: There were many similarities in the demographics, healthcare systems, government abortion legislation
and Down’s syndrome screening policy across the studied countries. However, the additional cost for Down’s
syndrome screening over and above standard antenatal care in the Netherlands and an emphasis on the ‘right
not to know’ about screening in this country were identified as potential explanations for the ‘low’ uptake rates of
Down’s syndrome screening in the Netherlands. The social context and positive framing of the offer at the service
delivery level may play a role in the relatively high uptake rates in Denmark.
Conclusions: This paper makes an important contribution to understanding how macro-level demographic, social
and healthcare delivery factors may have an impact on national uptake rates for Down’s syndrome screening. It has
suggested a number of policy level and system characteristics that may go some way to explaining the relatively
low uptake rates of Down’s syndrome screening in the Netherlands when compared to England and Denmark.
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The offer of prenatal Down’s syndrome screening (DSS)
is part of routine antenatal care in most of the European
Union. First trimester combined Down’s syndrome screen-
ing (DSS) is now the most used approach and combines
biochemical maternal serum screening and an ultrasound
fetal nuchal translucency measurement to calculate a
pregnancy specific risk factor. Following a ‘high risk’ re-
sult, for example higher than 1:200, diagnostic testing is
offered as an option. Following a positive diagnosis of
Down’s syndrome termination of pregnancy is offered as
an option in those countries were abortion is legal for fetal
abnormalities. Prenatal testing can therefore present so-
cial, emotional and social dilemmas and it is generally
accepted that parent’s decision to accept or decline the
offer of DSS should be informed by parental values and
made autonomously, that is without direction from health
professionals.
A review of early ‘demonstration’ projects in the
1990s, conducted to assess the practicality and acceptabil-
ity of DSS suggested that women in different countries
tended to make similar decisions about accepting DSS [1].
Across different types of tests in 17 studies in the USA
and Europe, average DSS uptake rates of around 80% were
reported. This also included findings from one study in
the Netherlands [2]. Once DSS programmes were imple-
mented within national health care systems, however,
uptake rates have shown to vary significantly across coun-
tries [3,4]. In the Netherlands, for example, DSS uptake
has been found to be low (<30%) when compared to other
northern European countries (74% in England and ≥ 90%
in Denmark) (Figure 1) [5-9]. These differences may
be considered surprising, given the findings from the
early demonstration projects and the apparently closeFigure 1 Introduction and trends of uptake of first trimester combine
Netherlands (squares).resemblance in cultural, social and healthcare factors across
these countries and, hence, they require explanation.
Personal decisions to accept or decline DSS are known
to be influenced by a range of psychosocial factors
including health beliefs and attitudes towards disability
and termination of pregnancy [10]. Certain social cul-
tural characteristics mediate these factors, for example,
uptake rates of DSS are lower in some minority ethnic
groups [11-13] and religious observance is an important
factor for some women choosing not to use DSS [14,15].
Hence variation in uptake rates may reflect differences
in individual choice, which then manifest in the regional
population in which the screening service is located.
However, highly significant variation in screening uptake
between close geographical locations in the UK, for
example, suggests that service delivery factors and the
healthcare context in which individual decisions are
made also play an important part in these differences
[16]. Service delivery and social structural differences
may also play a part in explaining the wide variation in
uptake across European countries; differences which
were not anticipated by the early demonstration projects.
The macro level influence that screening policies might
have on uptake at a national level has also not yet been
investigated at all.
The aim of this study was to consider whether struc-
tural and policy differences between the Netherlands,
England and Denmark could help explain the observed
variation in national uptake rates. Our research questions
were to identify similarities and differences in these three
countries across a) the socio-demographic population pro-
files, b) cultural factors, organization and structure of
health and social care systems and c) DSS policies and
programme characteristics.d screening in Denmark (diamonds), England (triangles) and the
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This study adopted a pragmatic qualitative approach to
help describe and explain relationships. To answer the
research questions we used a mixed methods approach
with an embedded design: a) analysis of relevant docu-
ments to describe differences and similarities within
established policies and programmes and b) to further
explore this information we performed in depth interviews
with relevant experts [17]. First, we studied central statis-
tical offices and legal documents to gain insight in demo-
graphic characteristics, cultural background, organization
and structure of healthcare in each of the three countries.
Second, we performed documentary analysis of primary
and secondary sources on relevant documents on DSS
policies and programme, and third, to enhance interpret-
ation of these findings we performed in-depth interviews
with relevant expert stakeholders in the participating
countries to provide insight in initial intentions and for-
mal rules of the national DSS policy and the impact on
performance [18,19].
National statistics and legal documents
Demographic characteristics, cultural background, orga-
nization and structure of healthcare in each of the
three countries were obtained from central statistical
offices and legal documents. Legal documents were
direct products of national Government and Ministries.
Secondary sources were used to supplement these findings
(Additional file 1).
Documentary analysis
Documentary analysis can be described as the ana-
lysis of documents that contain information about
the phenomenon to be studied [20]. In order to iden-
tify differences and similarities regarding DSS policies
and programme characteristics we performed docu-
mentary analysis on both primary and secondary sources
regarding DSS policies and characteristics (Additional
file 2).
Sample and procedure
First, individual prenatal DSS pathways were described
in each of three countries. Secondly, documents which
underpinned the different steps in these pathways were
purposively sampled. Documents were assessed for cri-
teria on relevance, reliability and origin, that is published
or approved by national screening organisations, national
government or national health boards. For example, in the
Netherlands, within the individual pathway DSS, there is a
‘step’ in which women have a right to refuse information.
Documents underlying this specific ‘step’ were searched in
National screening programme databases, websites, legal
websites, governmental websites and assessed for criteria
of reliability and origin. Documents underpinning this‘step’ are based on an interpretation of the principle
of autonomy and is incorporated in the screening
programme [21-23].
The sample of documents was obtained from National
screening databases (both websites and upon request),
governmental websites, national Health Council, national
Health board, ministries, legal websites, professional web-
sites and national health services websites. Secondary
sources were obtained from peer-reviewed literature to
supplement findings [24,18]. The quality control criteria
of authenticity, credibility, representatives, and meaning
were applied on selected documents and subsequently
selected for content analysis [25]. With the sample of doc-
uments underlying the individual pathways we intended
to design an overview of the ‘screening environment’ in
which individuals participate in DSS in the countries
studied.
We used content analysis to elucidate categories regard-
ing availability, provision and access to DSS in the three




Expert stakeholders were defined as persons having a
specific authority on the subject of DSS; holding a pos-
ition of leadership or influence in the development,
organisation or delivery of DSS screening organization
[19]. Expert stakeholders were anticipated to include
those with a scientific background or professional spe-
cialism in prenatal screening, or those involved in DSS
related policy-making. Purposive sampling of expert
stakeholders using snowballing techniques identified 15
people for interview; four were based in the Netherlands,
five in England and six in Denmark. Snowball sampling
is commonly used where expert knowledge is the pre-
requisite for inclusion in a sample. The research starts
with a small number of known stakeholders who then
identify other important stakeholders who meet the
study inclusion criteria [26]. In this study we started with
three initial informants; persons holding a leading position
in the national DSS programme (the Netherlands and
England) or leading position of influence in the deve-
lopment in DSS (Denmark). The initial informant than
nominated the participants in their country who met
the eligibility criteria for the study. In the Netherlands
two professional specialists were identified, and an ex-
pert involved in policy making and development. In
Denmark, three professional specialists were identified,
of which two were also involved in research. Besides an
expert in policy making and an expert on development
and research were identified. In England two profes-
sional specialists were identified, both also involved in
development. Furthermore an expert in research was
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programme.
Development of the interview schedule
Prior to the interviews the researchers explicitly dis-
cussed their personal views about DSS to reflect on how
subjective and intersubjective elements could influence
data collection, analysis and interpretation [19,27].
The interview schedule was informed by data from the
documentary analysis, and part of the interviews were
concerned with validating data found in the documen-
tary analysis, checking on apparent inconsistencies or
‘filling in’ missing data identified [19]. After performing
a pilot interview, the researchers discussed the interview
schedule, disagreements were discussed until consensus
was reached.
Ethical approval
Ethical approval for this study was obtained for par-
ticipants employed by the National Health Service via
the National Research Ethics Service in England (ref-
erence number 11/NE/0166). In Denmark (http://www.
cvk.sum.dk/English/actonabiomedicalresearch.aspx) and
the Netherlands (http://www.ccmo.nl/en/non-wmo-research)
ethical approval was not required for research involving
staff only.
Interview procedure
The interviews were performed at the interviewee’s
workplace. Two researchers were present at each inter-
view (SK, YV) [19]. The interviews were undertaken in
English in England and Denmark, and in Dutch in the
Netherlands. With the permission of participants, the in-
terviews were digitally recorded.
Analysis
All interviews were transcribed verbatim by the resear-
chers. After transcription, the interviewees were given
the chance to respond to the interview transcription on
accuracy only. The researchers read the transcripts and
discussed first impressions, thoughts and initial analysis.
The researchers identified themes in the transcripts and
emphasized on value of informed choice, influence on
screening choices and the impact of financial consi-
derations [28]. The Dutch data were analysed first and
subsequently translated into English.
The transcriptions were coded and stored on a university
firewall protected secure server, accessible via password for
security and safety, prior to electronic transfer to Utrecht
Medical Centre for access and storage in the Netherlands.
Data were removed from audio recorder and computer
servers in Denmark and England once safe transfer was
completed and secured.Results
Documentary analysis
Population characteristics, health and social care
Table 1 summarises the known basic demographic data
of the three countries. Birth rates, maternal age, percent-
age of the population born outside each country, and rates
of tertiary education were similar across countries. Re-
ported religious affiliation was substantially lower in the
Netherlands, although measures of religious observance
were not available. Gross Domestic Product (GDP) was
lowest in the UK but all three countries were highly eco-
nomically developed and in the top quartile of the United
Nation’s Human Development Index.
Table 2 summarises some key information about health
and social care systems including legislation available for
disabled people and their families.
Equal access to basic healthcare services was guaran-
teed by all systems and monitored by the national govern-
ments. Although healthcare systems could be categorised
differently, National Healthcare Services (Denmark and
England) and Social Security Healthcare system (the
Netherlands), all three countries provided a relatively high
level of social and health care for disabled individuals
when compared to lower income countries, although
service coverage was not assessed. Across all countries
financial provision and services for disabled people aimed
to support the principle of equal rights and equality of
opportunities in concordance with the United Nations
Standard Rules on the Equalization of Opportunities for
Persons with Disabilities [29-32].
Table 3 summarises legislation relevant to termination
of pregnancy in the three countries. Termination of
pregnancy (TOP) for social reasons was legal in all the
three countries studied and at no cost at point of delivery.
The gestational age at which a TOP can legally be per-
formed differed between countries. Denmark was the
most restrictive in terms of gestational limits. The UK
was the most liberal in terms of termination for fetal
anomaly with no upper gestation limit where “there is a
substantial risk that if the child were born it would
suffer from such physical or mental abnormalities as to
be seriously handicapped”[33].
Availability, provision and access to DSS in the Netherlands,
England and Denmark
The primary and secondary documents that we used for
the analysis can be found in Additional file 2, and were
published between 1999–2012.
The participating countries all have a current national
DSS programme. Figure 2 gives an overview of the time-
lines by country in terms of DSS provision [34-39,1].
Introduction of the different programmes and uptake
rates have shown a different trend, although uptake
increased in all three countries, over time, England and
Table 1 Population characteristics
The Netherlands United Kingdom* Denmark
Birth rate per 1000, 2010 11.1 13.0 11.4
Maternal age, 1st child, 2010 29.4 29.5 29.1
Reported religious affiliation (2009) 56% 85% 80%
Foreign-born population (2008) 10,9% 11% 8.8%
2.5% EU 3.5% EU 2.6% EU
8.4% Non EU 7.5% Non EU 6.2% Non EU
% of population aged 30–34 yrs with tertiary education qualifications (2009) 35.8 37.9 41.2
GDP per capita in PPS** 133 112 127
*Data for England only available at United Kingdom level i.e. the four countries including England.
**Gross Domestic Product in Purchasing Power Standards.
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(Figure 1) [8,9,40-42]. In England, due to a change in
policy in 2004 to make DSS available to all pregnant
women, all hospitals now have a DSS programme in
place. In Denmark the DSS programme was adopted in
2004 and in 2006 all women had access to the programme.
In the Netherlands the programme was fully implemented
in 2007 [7-9].
In all three countries, it is policy for DSS to be
available for all pregnant women, and first-trimester
(combined) screening is the standard. An opt-in system
is used for participation in DSS [36,23,43,44]. DSS comes
within national antenatal healthcare in all the three coun-
tries, and while DSS is available from private healthcare
companies it is probably used by a small proportion
of the pregnant population, although exact figures are
unknown.
All three countries provide national information leaflets
to pregnant women that show close resemblance on
content on terms of informed choice, purpose and
performance, knowledge of tested conditions, knowledgeTable 2 Health and social care legislation and funding
The Netherlands
Healthcare system Social Security Healthcare system
Funding of healthcare system Earmarked premiums
Organisation healthcare system Health care provided by non-profit
hospitals and individual practitioners
Strong influence of healthcare
providers and (social) insurers
Government responsible for accessibility
affordability and quality of healthcare
Legislation regarding equality
for disabled individuals
Act on Equal Treatment of Disabled and
Chronically Ill People (2003) (WGBH/CZ)
Wet gelijke behandeling op grond van
handicap of chronische ziekte
*Data for England only available at United Kingdom level i.e. the four countries inclof interpretation of (possible) test results, knowledge of
further diagnostic options. Information on possibilities if
DS is diagnosed was only mentioned in English and
Danish leaflets [45-47].
The guidelines for information provision differed
between the UK and the Netherlands and Denmark
in respect of the ‘right not to know’ [36,23,43].
In the Netherlands and Denmark the ‘right not to
know’ is explicitly described in legislation regarding
prenatal screening. The ‘right not to know’ is founded
on an ethical principle which emphasizes patient auton-
omy and gives patients the right to refuse certain medical
information. No such principle is included in screening
guidelines or policy in England. Only in the Netherlands
women are explicitly asked if they want information on
DSS before information was provided [36,23].
In England and Denmark, DSS is free at the point of
delivery for all pregnant women [36,43]. In the Netherlands
DSS is reimbursed only for women 36 years of age and
over or those at high prior risk for fetal anomalies; women
younger than 36 years of age and with no prior risk areUnited Kingdom* Denmark
National Health Service National Healthcare system
General taxation General taxation
Stated owned hospitals and
general practitioners have
contracts with NHS
State owned hospitals and general
practitioners have contracts with NHS
Strong influence of state:
SSSMinister of Health
responsible for budget
Strong influence of state: Minister
of Health responsible for budget
,
Equality Act (2010) Parliamentary Resolution on equal
opportunities for and equal treatment
of people with disabilities (1993) (BSF 43)
Folketingsbeslutning om ligestilling og
ligebehandling af handicappede med
andre borgere
uding England.
Table 3 Abortion legislation and funding
The Netherlands United Kingdom* Denmark
Termination of pregnancy
(TOP) for social reasons
Legal until 24 weeks
gestation
Legal until 24 weeks gestation Legal until 12 weeks gestation
TOP for fetal anomalies After 24 weeks only
in very limited cases
No gestational limit if there is a substantial risk the
child would suffer from such physical or mental
abnormality as to be seriously handicapped
Permitted up to 22 weeks if there is
a substantial risk that the child would
suffer from severe mental or physical
abnormality
Payment for TOP Free at the point of delivery Free at the point of delivery Free at the point of delivery
*Data for England only available at United Kingdom level i.e. the four countries including England.
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in the prenatal screening programme [23,48].
Stakeholder interviews: qualitative data
The transcribed interviews were thematically analysed.
The identified themes were: value of informed choice,
influence on screening choices and the impact of financial
considerations [28].
The value of informed choice
In all three countries the informed and autonomous
choice of women in relation to DSS is enshrined in policy
and practice guidelines. During interviews, stakeholdersFigure 2 Timelines of implementation of DSS in Denmark, England an
national programmes.also emphasised these values in the context of screening
delivery. For example English stakeholders commented:
“….there are more people being offered the test,
but if the question is, are we encouraging women’s
decision one way rather than another, to have
a test or not, the answer is definitely not…”
(C2-English, research).
“…we don't want to have an uptake target, because it
is about choice....”(C1- English, policy/ development).
Danish stakeholders agreed with this position:d the Netherlands. Grey scales indicate identical elements within the
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that there is a choice here and then they will
actively have to say yes or no” (B2-Danish,
professional specialism/research).
“I have spoken to thousands of women……they
are very pragmatic and it's also my impression
actually that Danish women take this seriously….
.even if they have differences in education right now,
they seemed to understand the whole aspects of this…”
(B6-Danish, development/research).
Dutch stakeholder also recognised the value of infor-
med choice:
“….being explicitly informed before making a choice is
important to consider all the pro’s and con’s before
making a choice…..” (A1-Dutch, policy/development).
“…women are being counselled in a non-directive way,
so they are able to make an individual choice....”
(A4-Dutch, professional specialism).
Influences on screening choices
At the same time as agreeing that informed choice
was enshrined in policy and delivered in practice,
stakeholders acknowledged the influence that others,
including healthcare professionals, might have on uptake
of DSS
“…the uptake is very much influenced by
what the midwife says to them....and also of
what they are hearing from family and friends.
Their preconceived ideas and what is being said to
them by the midwife is going to be what decides
what they do” (C3-English, professional specialism/
development).
“....the uptake is influenced by the information that is
available and how the screening is offered and how
it is brought across by the healthcare professional”
(C4-English, development).
The countries all followed an ‘opt-in’ system for DSS,
however the Danish stakeholders also recognised the
social context of antenatal care and the way that the offer
was framed influenced the options women appeared to
realistically have.
“…a lot of women make the choice they feel this is
reasonable, and they use the fact, that colleagues,
their sisters etcetera went for screening…I probably
think that in practice terms, it is probably an
opt-out, whereas it intended to be an opt-in….”
(B6-Danish, development/research).“….it’s a culture signal…..and you know from your
sister when she was pregnant, or your best friend
when she was pregnant, how it is a good thing to
do….” (B5-Danish, policy/development).
Danish stakeholders also suggested that a test offered by
government could be perceived as a recommendation:
“…..and if you present an offer.......a woman
has to make a decision and it is very hard to
say no to something, off course it is like that,
so there can be a pressure just by presenting it…”
(B4-Danish, professional specialism/research).
“…[it] means that some women may think
that this is a test recommended by the government
and therefore equals ‘this must be good”
(B1-Danish, professional specialism/research).
“….because the offer is made by the government,
there might be people who say I cannot decide,
I will go with the flow....”(B2-Danish, professional
specialism/research).
In Denmark, the opt in process was seen as important
in supporting an active informed choice and helping to
protect against just ‘going with the flow’.
“The woman has to make an active choice of
saying I want this screening…..women have to
book on the internet or make a phone call…..”
(B1-Danish, professional specialism/research).
Some Dutch stakeholders voiced concerns about an
over emphasis on informed choice.
“…I sometimes think, we put too much effort on
informed choice…..in normal life how many real
informed choices do we actually make…..”
(A3-Dutch, professional specialism).
In one case this was given as a reason for the relatively
low uptake in the Netherlands.
“….the effort being made on informed choice can be of
influence on low uptake rates in the Netherlands….”
(A4-Dutch, professional specialism).
In the Netherlands the ‘right not to know’ was explicitly
recognised by Dutch stakeholders
“Before counselling women are asked if
they want information on the test” (A4-Dutch,
professional specialism).
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know about any prenatal test, then that’s also ok, one
shouldn’t overwhelm women if they don’t want that”
(A1-Dutch, policy/development).
On the other hand, it was recognised that enshrining
this right in practice may produce a dilemma for the DSS
programme and informed choice:
“....there is a problem attached to it [the right
not to know]....if you ask somebody if they
want to know [about DSS], and they don’t,
is it clear for the parents what it is about?....
do they exactly know about the consequences?”
(A3-Dutch, professional specialism).
In Denmark the right not to know also has legal stand-
ing but does not appear to be implemented as ‘strongly’
as in the Netherlands. It was recognised again by a Danish
stakeholder that the context of an offer affects the way in
which this right is perceived.
“....women have the right not to know, but when you
offer the screening you are already sort of pressurizing
it…”(B6-Danish, development/research).
In England this ‘right not to know’ is not stated in
legislation, although in practice and in light of the
emphasis on informed choice, stakeholders believed
that midwives would likely to be sensitive to the wishes
of a woman who does not want to discuss DSS any
further:
“So the subject is raised with everybody, if she says, no,
I don’t want to hear anything more, then she won’t be
told anything more….” (C2-English, research).
Financial considerations and impact on screening choices
Unlike in England and Denmark, in the Netherlands,
pregnant women are charged a fee for DSS unless
they are older than 36 years. Some Dutch stake-
holders believed that this fee has an influence on up-
take rates:
“……For some people the charge of €160,00 could
cause distrust. For some people the amount of
money has impact on their available budget…..”
(A4-Dutch, professional specialism).
”….in one Dutch region where the test was
reimbursed for everybody, the uptake increased
by 50%.....but one could question whether these
women were able to make an informed choice…”
(A3-Dutch, professional specialism).Others were less confident on the effect of the fee
charged:
“.…money can play a role in decision making,
but that is something we don’t know yet”
(A1-Dutch, policy/development).
“....I wonder whether the fee of €160,00
could be a reason to decline the test.....”
(A2-Dutch, development/research)
“preliminary research showed that costs




With this study we considered structural and policy differ-
ences between the Netherlands, England and Denmark to
explain observed variation in national uptake rates. Except
for religion, we found many similarities in demographics.
Health and social care policies were also comparable in
the three countries. However, the additional cost for DSS
over and above standard antenatal care in the Netherlands
and an emphasis on the ‘right not to know’ about screen-
ing in this country were identified as potential explana-
tions for the ‘low’ uptake rates of DSS in the Netherlands.
The social context and positive framing of the offer at the
service delivery level may play a role in the relatively high
uptake rates in Denmark.
Population characteristics
Our survey of basic demographics showed, superficially
at least, more similarities than differences in population
characteristics. Religious affiliation, which has frequently
been associated with lower uptake of screening [14,15]
was actually least evident in the Netherlands data. How-
ever, whether religious affiliation equates to religious belief
is not necessarily the case. For example, Danish citizens
are registered as members of the Danish church unless
they actively take back their registration. In England, while
women may not have a strong religious affiliation they
may still, culturally align themselves with the church. This
may partly be due to the strong link between the church
and the English education system identification, for ex-
ample. In conclusion, there was no clear explanation that
screening uptake rates were closely aligned with population
characteristics in the direction that would be predicted by
the literature.
Screening policy and programmes
Our investigation aimed to find some explanations for
the wide variation in screening uptake across the three
European countries within the way screening programmes
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consider the structural factors which may contribute to
the Netherlands having a relatively low DSS uptake rate
compared to the other nations. We will consider these
factors first.
In this study we were able to identify two specific
characteristics in the Dutch DSS programme policy
which were different to Denmark and England. The first
was the ‘strong’ implementation of the right not to know
principle, and the second was the charged fee for
DSS in women under 36 years old with no history of
fetal anomaly.
To understand the context of these two policy points
it is important to understand the historical context of
DSS in the Netherlands. From 1991 until 2004 an exten-
sive public debate took place between government,
professional groups, patient organisations and Health
Council. As a result of this, a universal DSS programme
promoted by the government was considered to com-
municate reduced acceptance of disabled individuals.
There were fears of ‘genetic cleansing’ via the promotion
of abortion to prevent the birth of disabled children.
In addition, the direction of the debate was against
medicalization of pregnancy and the generation of what
was considered unnecessary anxiety in pregnancy [49-53].
With the implementation of the current screening pro-
gramme, the Dutch government has tried to reach a com-
promise. By offering DSS to all women equal access was
guaranteed, but the restrained policy and the age limit was
maintained by the implementation of the ‘right not to
know’ and a fee charged [52].
Garcia et al. have stated that the moral significance of
prenatal testing is inseparably bound with the social
context in which it is practiced [54]. The current Dutch
screening programme is an outcome of a large public
debate and therefore reflects the social context in which
individual decision-making has to take place. Charging a
fee for DSS where all other pregnancy related healthcare
is covered conveys a message that to have screening is not
‘just’ routine, and thus DSS in the Netherlands has not
become normalised in antenatal care as it has, for ex-
ample, in Denmark [53]. The direct effect of this policy on
individual decision making is unclear, but it is part of the
context in which Dutch pregnant women make their deci-
sions and could be an explanation of the lower uptake in
the Netherlands when compared to countries where uni-
versal screening is actively offered to all pregnant women
regardless of age, free at the point of delivery.
More difficult to explain from our data is the significant
difference in uptake between England and Denmark. One
explanation may be the way the offer of DSS is presented
in Denmark compared to England. Danish stakeholders
acknowledged the role of healthcare professionals and
how screening can be perceived as a recommendationfrom the government, but were also convinced that the
‘opt in’ system prevented patients from making unin-
formed choices. Evidence for the role of healthcare pro-
fessionals on screening choices is mixed. Some studies
suggest that individual healthcare professionals’ attitudes
do not have a significant effect on women’s DSS choices
[55,16]. However, one UK study found that in services
where DSS uptake was high, health care professionals as a
group held a more positive attitude towards testing than
in services where uptake was lower [16]. The authors sug-
gested that “the observed association between healthcare
professionals’ attitudes and uptake rates by hospitals raises
the question of whether healthcare professionals’ attitudes
might influence systems of care, not just communication
with pregnant women” (p 868). It might be that on the
whole, Danish healthcare professionals hold more positive
attitudes towards DSS than do their English (or Dutch)
counterparts. The Danish stakeholders also recognised the
social context of DSS and the way that the offer is framed
influences the options women appear to have. In a country
where screening uptake has historically been relatively
high, women may themselves hold more positive views
about DSS and this is likely to have some influence on the
choices of other pregnant women in their social milieu
[54,56]. Danish stakeholders comments about Denmark
appearing to offer an ‘opt out’ programme, suggest a dif-
ferent frame associated with loss of opportunities (e.g. if
everyone else is having it), different from the ‘frame’ of
‘the right not to know’ and costs in the Netherlands.
Presenting participation as an opportunity (both opt-in
and opt-out) appear to bias decision making and affects
uptake. Opportunity frames seem to draw attention on
treatment and therefore influence decision making [57].
The Danish perception of an ‘opt out’ programme, could
also be a reflection of the context and service delivery. As
these are important variables in determining uptake this
might play a role in the high uptake rates in Denmark
[58]. In England, the emphasize on informed decision
making and opt-in, frames the offer in a different way, but
the effect of this on uptake rates is less clear. The absence
of costs associated with the utilization of testing and
emphasize on informed decision making (opportunity
framing) might account partly for the English uptake
rates [57,59,60].
However, these are suppositions and further empirical
research is required to address these possible social and
cultural differences within national DSS services and the
countries within which they are situated.
Contribution to knowledge and limitations and future
research
This paper has made an important preliminary attempt to
consider how macro-level demographic, social and health-
care delivery factors may have an impact on national
Crombag et al. BMC Health Services Research 2014, 14:437 Page 10 of 11
http://www.biomedcentral.com/1472-6963/14/437uptake rates for DSS. It has suggested a number of policy
level and system characteristics that may go some way to
explaining the relatively low uptake rates of DSS in the
Netherlands when compared to England and Denmark.
An important limitation of this study was that the pri-
mary researchers were Dutch, although they had a good
knowledge of English. The use of primary documents
often requires knowledge of language of the country.
This resulted in potentially less primary data being col-
lected from the Denmark when compared to the other
two groups.
Conclusion
This study aimed to assess the impact of a range of
national characteristics in the Netherlands, England and
Denmark on DSS uptake rates. Our results indicate that
utilization of DSS may be influenced by the way it is
being offered at both policy and service delivery level,
and that the ‘offer’ is also contextualised within the
woman’s social environment. It is proposed that in the
Netherlands having to pay for DSS, the public debate
that preceded this decision and the emphasis on the right
not to know, are in combination likely to explain the rela-
tively low uptake of DSS. In contrast, a social context
where screening is viewed as routine and the offer framed
possibly, if not strongly, as a recommendation may play a
role in the relatively high uptake of DSS in Denmark.
Future research can build on this preliminary work to as-
sess empirically the effect of different aspects of national
policies and healthcare culture on individual decision
making. Such work is likely to require quantitative, quali-
tative, and observational approaches.
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